Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells

Leukemia and Lymphoma

Volumn 45, Issue 2, 2004, Pages 237-245

  Holtz, Melissa S ^a   Bhatia, Ravi ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

BCR ABL; Chronic myelogenous leukaemia; Hematopoietic progenitors; Imatinib mesylate; Stem cells

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ALPHA INTERFERON; ARSENIC TRIOXIDE; BCR ABL PROTEIN; CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; LONAFARNIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMOGENESIS; PRIORITY JOURNAL; REVIEW;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; STEM CELLS;

EID: 0842322903     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000151905     Document Type: Review

References (45)

1. Fialkow, P.J., Jacobson, R.J. and Papayannopoulou, T. (1977) "Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage", American Journal of Medicine, 63, 125-130.
2. Rowley, J.D. (1973) "Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining", Nature, 243, 290-293.
3. Daley, G.Q. and Baltimore, D. (1988) "Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein", Proceedings of the National Academy of Sciences of the USA, 85, 9312-9316.
4. Daley, G.Q., Van Etten, R.A. and Baltimore, D. (1990) "Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome". Science, 247, 824-830.
5. Pear, W.S., Miller, J.P., Xu, L., Pui, J.C., Soffer, B., Quackenbush, R.C., et al. (1998) "Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow", Blood, 92, 3780-3792
6. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B.J., et al. (1996) "Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative", Cancer Research, 56, 100-104.
7. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., et al. (1996) "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells", Nature Medicine, 2, 561-566.
8. Heinrich, M.C., Griffith, D.J., Druker, B.J., Wait, C.L., Ott, K.A. and Zigler, A.J. (2000) "Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor", Blood, 96, 925-932.
9. Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N.B., et al. (1997) "CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins", Blood, 90, 4947-4952.
10. le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., et al. (1999) "In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor", Journal of the National Cancer Institute, 91, 163-168.
11. Deininger, M.W., Goldman, J.M., Lydon, N. and Melo, J.V. (1997) "The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells", Blood, 90, 3691-3698.
12. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., et al. (2001) "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", New England Journal of Medicine, 344, 1031-1037.
13. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., (2001) "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome". New England Journal of Medicine, 344, 1038-1042.
14. O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., et al. (2003) "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia", New England Journal of Medicine, 348, 994-1004.
15. Marley, S.B., Deininger, M.W., Davidson, R.J., Goldman, J.M. and Gordon, M.Y. (2000) "The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte- macrophage progenitors from patients with chronic myeloid leukemia", Experimental Hematology, 28, 551-557.
16. Gordon, M.Y., Marley, S.B., Lewis, J.L., Davidson, R.J., Nguyen, D.X., Grand, F.H., et al. (1998) "Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM", Journal of Clinical Investigation, 102, 710-715.
17. Marley, S.B., Davidson, R.J., Lewis, J.L., Nguyen, D.X., Eades, A., Parker, S., et al. (2001) "Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo", Leukaemia Research, 25, 997-1002.
18. Kasper, B., Fruehauf, S., Schiedlmeier, B., Buchdunger, E., Ho, A.D. and Zeller, W.J. (1999) "Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors", Cancer Chemotherapy Pharmacology, 44, 433-438.
19. Holtz, M.S., Slovak, M.L., Zhang, F., Sawyers, C.L., Forman, S.J. and Bhatia, R. (2002) "Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation", Blood, 99, 3792-3800.
20. Graham, S.M., Jorgensen, H.G., Allan, E., Pearson, C., Alcorn, M.J., Richmond, L., et al. (2002) "Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro", Blood, 99, 319-325.
21. Horita, M., Andreu, E.J., Benito, A., Athena, C., Sanz, C., Benet, I. et al. (2000) "Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL", Journal of Experimental Medicine, 191, 977-984.
22. Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D.S., Sawyers, C.L., et al. (2003) "Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment", Blood, 101, 4701-4707.
23. Wolff, N.C. and Ilaria, R. L., Jr. (2001) "Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571", Blood, 98, 2808-2816.
24. Hochhaus, A., Kreil, S., Corbin, A.S., La Rosee, P., Muller, M.C., Lahaye, T., et al. (2002) "Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy", Leukemia, 16, 2190-2196.
25. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., et al. (2001) "Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification", Science, 293, 876-880.
26. Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J., et al. (2002) "Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia", Cancer Cell, 2, 117-125.
27. von Bubnoff, N., Schneller, F., Peschel, C. and Duyster, J. (2002) "BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. [comment]", Lancet, 359, 487-491.
28. Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Lai, J.L., Philippe, N., Facon, T., et al. (2002) "Several types of mutations of the AN gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment", Blood, 100, 1014-1018.
29. Campbell, L.J., Patsouris, C., Rayeroux, K.C., Somana, K., Januszewicz, E.H. and Szer, J. (2002) "BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration". Cancer Genetics and Cytogenetics, 139, 30-33.
30. Uchida, N., Combs, J., Chen, S., Zanjani, E., Hoffman, R. and Tsukamoto, A. (1996) "Primitive human hematopoietic cells displaying differential efflux of the rhodamine 123 dye have distinct biological activities", Blood, 88, 1297-1305.
31. Goodell, M.A., Brose, K., Paradis, G., Conner, A.S. and Mulligan, R.C. (1996) "Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo", Journal of Experimental Medicine, 183, 1797-1806.
32. Goodell, M.A., Rosenzweig, M., Kim, H., Marks, D.F., DeMaria, M., Paradis, G., et al. (1997) "Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species", Nature Medicine, 3, 1337-1345.
33. Scharenberg, C.W., Harkey, M.A. and Torok-Storb, B. (2002) "The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors", Blood, 99, 507-512.
34. Tipping, A.J., Mahon, F.X., Zafirides, G., Lagarde, V., Goldman, J.M. and Melo, J.V. (2002) "Drug responses of imatinib mesylateresistant cells: synergism of imatinib with other chemotherapeutic drugs", Leukemia, 16, 2349-2357.
35. Thiesing, J.T., Ohno-Jones, S., Kolibaba, K.S. and Druker, B.J. (2000) "Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells", Blood, 96, 3195-3199.
36. Scappini, B., Onida, F., Kantarjian, H.M., Dong, L., Verstovsek, S., Keating, M.J., et al. (2002) "In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells", Cancer, 94, 2653-2662.
37. Marley, S.B., Davidson, R.J., Goldman, J.M. and Gordon, M.Y. (2002) "Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia", British Journal of Haematology, 116, 162-165.
38. La Rosee, P., Johnson, K., O'Dwyer, M.E. and Druker, B.J. (2002) "In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia", Experimental Hematology, 30, 729-737.
39. Hoover, R.R., Mahon, F.X., Melo, J.V. and Daley, G.Q. (2002) "Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336", Blood, 100, 1068-1071.
40. Klejman, A., Rushen, L., Morrione, A., Slupianek, A. and Skorski, T. (2002) "Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571", Oncogene, 21, 5868-5876.
41. Nimmanapalli, R., O'Bryan, E., Huang, M., Bali, P., Burnette, P.K., Loughran, T., et al. (2002) "Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin", Cancer Research, 62, 5761-5769.
42. La Rosee, P., Corbin, A.S., Stoffregen, E.P., Deminger, M.W. and Druker, B.J. (2002) "Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)", Cancer Research, 62, 7149-7153.
43. Huang, M., Dorsey, J.F., Epling-Burnette, P.K., Nimmanapalli, R., Landowski, T.H., Mora, L.B., et al. (2002) "Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells", Oncogene, 21, 8804-8816.
44. Wisniewski, D., Lambek, C.L., Liu, C., Strife, A., Veach, D.R., Nagar, B., et al. (2002) "Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases", Cancer Research, 62, 4244-4255.
45. Kraker, A.J., Hartl, B.G., Amar, A.M., Barvian, M.R., Showalter, H.D. and Moore, C.W. (2000) "Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors", Biochemical Pharmacology, 60, 885-898.